BackPharmaron Beijing , Ltd. Overview

Pharmaron Beijing , Ltd. Profit Margin

Pharmaron Beijing , Ltd. (3759.HK) has a profit margin of 11.1%, below the Healthcare sector average of 17.63%.

Get informed when a big investor buys or sells

+ Follow

Quarterly Profit Margin

11.27%
↓ 7.96% YoY

As of Sep 2026

Annual Profit Margin (TTM)

11.10%
↓ 1.02% YoY

Trailing 12 months ending Sep 2026

Average Profit Margin (Comparison Companies)

Loading

Profit Margin History

Loading

Profit Margin Comparison

Loading

Annual Profit Margin Growth Rate (%)

Loading

Pharmaron Beijing , Ltd. (3759.HK) FAQ

Pharmaron Beijing , Ltd. posts a profit margin of 11.1% as of September 2026. That compares with 11.21% in the prior-year period — down 1.0% year over year. That is below the Healthcare sector average of 17.63%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Pharmaron Beijing , Ltd.'s profit margin was 11.21%. The latest reading is 11.1% — a 1.0% year-over-year decrease (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 17.63% is typical. Pharmaron Beijing , Ltd.'s 11.1% is lower that level. That is roughly 37.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Pharmaron Beijing , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 11.1% as of September 2026; use YoY and peer views to separate noise from signal.

Context for 3759.HK's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 17.63%), and (3) consistency with growth and profitability. This page covers the first two; Pharmaron Beijing , Ltd.'s other metric pages and overview cover the third.